178 related articles for article (PubMed ID: 38886844)
1. CAR-T cell-derived exosomes: a new perspective for cancer therapy.
Sani F; Shojaei S; Tabatabaei SA; Khorraminejad-Shirazi M; Latifi M; Sani M; Azarpira N
Stem Cell Res Ther; 2024 Jun; 15(1):174. PubMed ID: 38886844
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy.
Tang XJ; Sun XY; Huang KM; Zhang L; Yang ZS; Zou DD; Wang B; Warnock GL; Dai LJ; Luo J
Oncotarget; 2015 Dec; 6(42):44179-90. PubMed ID: 26496034
[TBL] [Abstract][Full Text] [Related]
3. CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity.
Fu W; Lei C; Liu S; Cui Y; Wang C; Qian K; Li T; Shen Y; Fan X; Lin F; Ding M; Pan M; Ye X; Yang Y; Hu S
Nat Commun; 2019 Sep; 10(1):4355. PubMed ID: 31554797
[TBL] [Abstract][Full Text] [Related]
4. Generation and functional characterization of CAR exosomes.
Wang C; Fu W; Lei C; Hu S
Methods Cell Biol; 2022; 167():123-131. PubMed ID: 35152990
[TBL] [Abstract][Full Text] [Related]
5. [Combining CAR-T cells anti-tumoral activity with exosomes properties: an innovative approach to fight cancer].
Fusilier Z; Ferran H
Med Sci (Paris); 2020; 36(6-7):655-658. PubMed ID: 32614317
[TBL] [Abstract][Full Text] [Related]
6. Emerging Strategies to Overcome Current CAR-T Therapy Dilemmas - Exosomes Derived from CAR-T Cells.
Hu D; Yang R; Wang G; Li H; Fan X; Liang G
Int J Nanomedicine; 2024; 19():2773-2791. PubMed ID: 38525009
[TBL] [Abstract][Full Text] [Related]
7. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.
Niu Z; Wu J; Zhao Q; Zhang J; Zhang P; Yang Y
Front Immunol; 2024; 15():1385571. PubMed ID: 38680498
[TBL] [Abstract][Full Text] [Related]
8. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment.
Mollanoori H; Shahraki H; Rahmati Y; Teimourian S
Hum Immunol; 2018 Dec; 79(12):876-882. PubMed ID: 30261221
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
11. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
12. A CAR T-inspiring platform based on antibody-engineered exosomes from antigen-feeding dendritic cells for precise solid tumor therapy.
Fan M; Liu H; Yan H; Che R; Jin Y; Yang X; Zhou X; Yang H; Ge K; Liang XJ; Zhang J; Li Z
Biomaterials; 2022 Mar; 282():121424. PubMed ID: 35196606
[TBL] [Abstract][Full Text] [Related]
13. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
[TBL] [Abstract][Full Text] [Related]
14. CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers.
Picanço-Castro V; Swiech K; Malmegrim KCR; Covas DT
Methods Mol Biol; 2020; 2086():1-10. PubMed ID: 31707664
[TBL] [Abstract][Full Text] [Related]
15. Engineered exosome-mediated messenger RNA and single-chain variable fragment delivery for human chimeric antigen receptor T-cell engineering.
Si K; Dai Z; Li Z; Ye Z; Ding B; Feng S; Sun B; Shen Y; Xiao Z
Cytotherapy; 2023 Jun; 25(6):615-624. PubMed ID: 36828738
[TBL] [Abstract][Full Text] [Related]
16. CAR Cells beyond Classical CAR T Cells: Functional Properties and Prospects of Application.
Minina EP; Dianov DV; Sheetikov SA; Bogolyubova AV
Biochemistry (Mosc); 2024 May; 89(5):765-783. PubMed ID: 38880641
[TBL] [Abstract][Full Text] [Related]
17. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
Qu J; Mei Q; Chen L; Zhou J
Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
[TBL] [Abstract][Full Text] [Related]
19. Generation of CAR-T Cells for Cancer Immunotherapy.
Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
[TBL] [Abstract][Full Text] [Related]
20. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
